Thomas C. Abshire, MD
Professor of Medicine and Pediatrics Senior Investigator, Blood Research Institute, Versiti
Residency, Pediatrics, David Grant Medical Center, 1979-1982
Fellowship, Pediatric Hematology/Oncology, University of Colorado Health Sciences Center, 1985-1988
Dr. Thomas Abshire is a Senior Investigator, VBRI as well as Professor of Pediatrics, Medicine and the CTSI of SE WI at the Medical College of Wisconsin. Other positions he holds at Versiti are: Executive VP Medical Sciences Institute (MSI) and Chief Medical Officer.
He has been a federally sponsored Principal Investigator (since 1991) and an NIH funded Co-Principal Investigator and PI (since 2002). After 14 years at Emory University, he was recruited to Versiti/BCW to lead a new clinical research program, the MSI, as Senior/Executive Vice President and Senior Investigator, VBRI. Previous to his position at Emory, he enjoyed a 20 year career in academic military medicine. Over his career, he has demonstrated strong leadership skills in several national hemostasis/thrombosis research organizations, including being past President of the Hemostasis and Thrombosis Research Society (HTRS) and past Chair, American Thrombosis and Hemostasis Network, (ATHN), an organization committed to development of a national database and to performing outcomes, population science and clinically-related research.
He has 30+ years experience as a clinical investigator and as PI, Co-PI or collaborator, and has been involved in 16 national/international trials. His most recent efforts have been focused on VWD with two completed projects, the VWD International Prophylaxis (VIP) Study (Abshire and Berntorp, Multiple-PI; MPI) and NIH R01, Comparative Effectiveness in the Diagnosis of VWD, Abshire and Montgomery, MPIs with recent continuation as Key Personnel in the 3rd renewal of the PPG, the Zimmerman Program on the Biology of VWD (2019-2024).
For the last 25 years, he has been fortunate to oversee the career development of over 35 physicians including residents, fellows and junior faculty, with half maintaining a focused interest in nonmalignant hematology and transfusion medicine. Additionally, 50% of these mentees have received either a mentored career award from the NIH, have been on an NHLBI T32 training grant or have been selected for the NIH loan repayment program.
He received the designation "Best Doctors" for 10 years while he was active seeing patients (2009 – 2018) at Froedtert Hospital.
(Gill JC, Conley SF, Johnson VP, Christopherson PA, Haberichter SL, Diaz CD, Strong TC, Zhang J, Simpson P, Abshire TC, Montgomery RR, Flood VH.) Blood Adv. 2020 01 14;4(1):100-105 PMID: 31905240 PMCID: PMC6960478 SCOPUS ID: 2-s2.0-85078147321 01/07/2020
(Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco-Johnson MJ, Joint Outcome Study Group Investigators.) Haemophilia. 2019 Sep;25(5):867-875 PMID: 31115111 PMCID: PMC7273872 05/23/2019
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.
(Holm E, Carlsson KS, Lövdahl S, Lail AE, Abshire TC, Berntorp E.) Haemophilia. 2018 Jul;24(4):628-633 PMID: 29626372 04/08/2018
(Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL, Zimmerman Program Investigators.) Ann Blood. 2018 Jan;3 PMID: 30135959 PMCID: PMC6100783 08/24/2018
(Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Hemophilia Inhibitor Research Study Investigators.) J Thromb Haemost. 2017 10;15(10):1971-1976 PMID: 28795528 PMCID: PMC5716470 08/11/2017
(Kulkarni R, Presley RJ, Lusher JM, Shapiro AD, Gill JC, Manco-Johnson M, Koerper MA, Abshire TC, DiMichele D, Hoots WK, Mathew P, Nugent DJ, Geraghty S, Evatt BL, Soucie JM.) Haemophilia. 2017 Mar;23(2):207-214 PMID: 27813214 PMCID: PMC5354941 11/05/2016
(Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH, Hemophilia Inhibitor Research Study Investigators.) J Thromb Haemost. 2016 10;14(10):1931-1940 PMID: 27501440 PMCID: PMC5083216 10/28/2016
(Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.) Blood. 2016 05 19;127(20):2481-8 PMID: 26862110 PMCID: PMC4874228 SCOPUS ID: 2-s2.0-84974556876 02/11/2016
(Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH, Hemophilia Inhibitor Research Study Investigators.) J Thromb Haemost. 2015 Jun;13(6):1036-42 PMID: 25780857 PMCID: PMC4512234 03/18/2015
(Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E.) Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8 PMID: 25688461 02/18/2015
(Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH, Hemophilia Inhibitor Research Study Investigators, Hemophilia Inhibitor Research Study Investigators.) J Thromb Haemost. 2015 Jan;13(1):47-53 PMID: 25354263 PMCID: PMC4383171 10/30/2014
(Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, Haemophilia Inhibitor Research Study Investigators.) Haemophilia. 2014 Mar;20(2):230-7 PMID: 24261612 PMCID: PMC4519821 11/23/2013